News brief­ing: Check­point reads out new in­ter­im mC­SCC da­ta; Taysha eyes $125M for its flash IPO

Check­point Ther­a­peu­tics has read out up­dat­ed in­ter­im Phase I da­ta for its an­ti-PD-L1 an­ti­body cosi­be­limab in a reg­is­tra­tion-en­abling co­hort of metasta­t­ic cu­ta­neous squa­mous cell car­ci­no­ma pa­tients. And the New York-based biotech plans to com­pete with ri­vals by “sub­stan­tial­ly low­er­ing” costs.

The in­ter­im re­sults, which were pre­sent­ed at ES­MO, showed Check­point’s drug achieved a 51.4% ob­jec­tive re­sponse rate (ORR) and 13.5% com­plete re­sponse (CR) rate — near­ly dou­bling the com­plete re­sponse rate ob­served dur­ing its last analy­sis, ac­cord­ing to the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.